Quality of Life in Men Undergoing Robotic Assisted Laparoscopic Radical Prostatectomy Versus Radical Retropubic Prostatectomy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2010 by Samsung Medical Center.
Recruitment status was  Not yet recruiting
Information provided by:
Samsung Medical Center
ClinicalTrials.gov Identifier:
First received: July 30, 2010
Last updated: NA
Last verified: June 2010
History: No changes posted
This study is prospective evaluation of quality of life in men undergoing robotic assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy.

Prostatic Neoplasms
Quality of Life

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Prospective Evaluation of Quality of Life in Men Undergoing Robotic Assisted Laparoscopic Radical Prostatectomy Vs. Radical Retropubic Prostatectomy

Resource links provided by NLM:

Further study details as provided by Samsung Medical Center:

Estimated Enrollment: 350
Study Start Date: August 2010
Estimated Study Completion Date: January 2014
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Detailed Description:

Preoperatively, enrolled patients will complete questionnaires called EPIC that will ask about urinary, sexual, bowel and hormonal function

At 1, 3,6,9 and 12 months after surgery, pateints will complete the questionnaires again.

All will be enrolled at Samsung Medical Center


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients diagnosed with prostate cancer

Inclusion Criteria:

  • Pathologic diagnosis of prostate adenocarcinoma
  • Clinical stage: AJCC (VI) stage T1-T2 N0M0
  • Primary treatment at Samsung Medical Center for prostate cancer using: radical retropubic prostatectomy, robotic prostatectomy

Exclusion Criteria:

  • Clinical Stage: T3, T4, nodal or distant metastasis
  • All kind of neoadjuvant, concurrent and adjuvant treatment
  • poor health forced a patient into dropout
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01173952

Contact: Sung Won Lee, M.D.& Ph.D. 82-2-3410-3552 drswlee@skku.edu
Contact: Deok Hyun Han, M.D.& Ph.D. 82-2-3410-6431 deokhyun.han@samsung.com

Sponsors and Collaborators
Samsung Medical Center
Study Chair: Sung Won Lee, M.D.& Ph.D. Department of Urology Samsung Medical Center
  More Information

Responsible Party: Sung Won Lee, M.D.& Ph.D./Professor, Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Urology Samsung Medical Center, Sungkyunkwan University School of Medicine
ClinicalTrials.gov Identifier: NCT01173952     History of Changes
Other Study ID Numbers: 2010-06-026 
Study First Received: July 30, 2010
Last Updated: July 30, 2010
Health Authority: South Korea: Institutional Review Board

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms

ClinicalTrials.gov processed this record on May 30, 2016